The lack of studies that evaluate and systematically analyze the available ERO1α results have partly contributed to the ambiguity around ERO1α, and whether it could be used as a reliable marker to predict the outcome of a cancer diagnosis or an effective target for treatment. This evidence concerns the gene ERO1A and cancer.